Pnd10 - Genius Rwe Study (Fingolimod Real World Evidence Italian Multicenter Observational Study in Multiple Sclerosis)preliminary Results

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1977
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International
Neurology
2015English

The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study

PLoS ONE
Multidisciplinary
2017English

Prm82 - Real World Evidence (Rwe) From Italian NHS-Aifa Registries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Real-World Outcomes in Fingolimod-Treated Patients With Multiple Sclerosis in the Czech Republic: Results From the 12-Month GOLEMS Study

Clinical Drug Investigation
MedicinePharmacology
2016English

Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis

Patient Related Outcome Measures
2017English

5psq-075 Safety Profile of Fingolimod in Real World Clinical Practice: A Preliminary Study

2020English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Pnd13 - Real World Evidence (Rwe) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (Dmts) in Relapsing-Remitting Multiple Sclerosis (Rrms) in Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

049 Real World Evidence (RWE) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (DMTS) in Relapsing-Remitting Multiple Sclerosis (RRMS) in Australia

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy